Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.

What Was Tested

The paper reports a study of Angiotensin II Type 1 Receptor Blockers in the context of osteoporosis and bone density, published as a randomized controlled trial.

The present study was designed to determine the effect of the angiotensin II receptor blocker candesartan on circulating osteoprotegerin (OPG) in hypertensive patients with multiple cardiovascular risk factors.

Why It Was Studied

The renin-angiotensin-aldosterone system (RAAS) has recently been considered as a possible link between bone and vascular disease.

Who Took Part

The study group was 69 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

Patients were evaluated for lipid profile, HbA1C, insulin, C-peptide, CRP, aldosterone, renin, homeostasis model assessment-insulin resistance (HOMA-IR) and OPG.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II Type 1 Receptor Blockers and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Biphenyl Compounds, Bone and Bones, Hemodynamics, Hypertension and Osteoprotegerin.

Author keywords: Angiotensin II receptor blocker and renin-angiotensin-aldosterone system.

What This Means in Plain Language

The paper is a randomized study of Angiotensin II Type 1 Receptor Blockers in 69 patients in people with osteoporosis and bone density.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Journal of the renin-angiotensin-aldosterone system : JRAAS), a journal based in England.

More context: Osteoporosis and bone density research.